Bright Minds Biosciences logo

Bright Minds BiosciencesNASDAQ: DRUG

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

22 March 2021

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$165.16 M
-32%vs. 3y high
51%vs. sector
-vs. 3y high
-vs. sector
-32%vs. 3y high
99%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Wed, 20 Nov 2024 00:09:25 GMT
$37.00$0.00(0.00%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

DRUG Latest News

Meet the Biotech Stock That Has Generated Nvidia-Like Returns in Less Than a Month
fool.com13 November 2024 Sentiment: POSITIVE

The reason for the stock's rapid ascent is a mystery.

CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
prnewswire.com06 November 2024 Sentiment: POSITIVE

NASHVILLE, Tenn. , Nov. 6, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that the United States (U.S.) Food and Drug Administration (FDA) granted Orphan Drug Designation and Rare Pediatric Disease Designation to Ifetroban for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD).

Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement
globenewswire.com04 November 2024 Sentiment: POSITIVE

VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) announces that further to its news release of October 18, 2024, the Company has closed a non-brokered private placement of 1,612,902 common shares in the capital of the Company (“Shares”) at a price of USD$21.70 per Share for aggregate gross proceeds of USD$35,000,000 (the “Offering”).

Bright Minds Biosciences: BMB-101's Phase 2 Trials Could Unlock Epilepsy Market Potential
seekingalpha.com30 October 2024 Sentiment: POSITIVE

Bright Minds Biosciences' BMB-101, a 5-HT2C receptor agonist, shows promise in treating drug-resistant epilepsy, with favorable Phase 1 safety and efficacy data. The company's proprietary platform targets serotonin regulation, aiming to create selective therapies with fewer side effects. DRUG's recent $35 million private placement funds Phase 2 trials, enhancing its financial outlook and potential for significant revenue if BMB-101 is successful.

Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data
globenewswire.com21 October 2024 Sentiment: POSITIVE

NEW YORK AND VANCOUVER, British Columbia, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (Bright Minds or the Company) (NASDAQ: DRUG), a biotechnology company focused on developing novel therapies for neurological and neuropsychiatric disorders, today announced that it is once again collaborating with Firefly Neuroscience, Inc. (Firefly) (NASDAQ: AIFF), an Artificial Intelligence (AI) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, to provide a full analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study, an open-label Phase 2 clinical trial evaluating the safety, tolerability, and efficacy of BMB-101, a highly selective 5-HT2C receptor agonist, in adult patients with classic Absence Epilepsy and Developmental Epileptic Encephalopathy (DEE).

Monster insider trading alert for this penny stock that rallied $3,700% in a week
finbold.com19 October 2024 Sentiment: POSITIVE

This week, the stock market witnessed a peculiar price movement involving biotech firm Bright Minds Biosciences (NASDAQ: DRUG), which skyrocketed to historic levels, and it seems several investors have profited significantly from this momentum.

Why did this penny stock skyrocket 1,500% in a day
finbold.com16 October 2024 Sentiment: POSITIVE

When most major equities recorded notable losses, the share price of biotech company Bright Minds Biosciences (NASDAQ: DRUG) experienced a meteoric rise, with minimal fundamental factors supporting this momentum.

Bright Minds Biosciences Stock Surges Almost 1,500%
marketbeat.com16 October 2024 Sentiment: POSITIVE

Bright Minds Biosciences NASDAQ: DRUG, a little-known biotech company, became the talk of the market yesterday after its stock skyrocketed by 1,445% in a single trading session. Typically trading under 1 million shares daily, the stock saw over 100 million shares change hands without any direct news.

Canadian psychedelics company Bright Minds shares rise 1,446% in one day
proactiveinvestors.co.uk16 October 2024 Sentiment: POSITIVE

Yesterday, Bright Minds Biosciences Inc (CSE:DRUG, OTCQB:BMBIF), a biotech in the field of psychedelics, saw its shares rocket by a frankly psychedelic-looking 1,445.8% to $38.49 from $2.50 at the start of the day.  At the request of the Canadian Investment Regulatory Organization (CIRO), Bright Minds confirmed that management "is unaware of any material changes in the company's operations that would account for the recent increase in market activity".

Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy
prnewswire.com12 September 2024 Sentiment: POSITIVE

Bright Minds Biosciences announces Phase 2 Clinical trial to evaluate BMB-101 in a group of drug-resistant epilepsy disorders with high unmet needs BMB-101 is a novel highly selective 5-HT2C agonist. Its G-protein biased agonism provides an improved mechanism of action for chronic dosing Financial runway extending into 2026 enabling key data readout Conference call & KOL Event – will be held as a webcast on September 25th at 10:00 ET  NEW YORK , Sept.

What type of business is Bright Minds Biosciences?

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

What sector is Bright Minds Biosciences in?

Bright Minds Biosciences is in the Healthcare sector

What industry is Bright Minds Biosciences in?

Bright Minds Biosciences is in the Biotechnology industry

What country is Bright Minds Biosciences from?

Bright Minds Biosciences is headquartered in United States

When did Bright Minds Biosciences go public?

Bright Minds Biosciences initial public offering (IPO) was on 22 March 2021

What is Bright Minds Biosciences website?

https://brightmindsbio.com

Is Bright Minds Biosciences in the S&P 500?

No, Bright Minds Biosciences is not included in the S&P 500 index

Is Bright Minds Biosciences in the NASDAQ 100?

No, Bright Minds Biosciences is not included in the NASDAQ 100 index

Is Bright Minds Biosciences in the Dow Jones?

No, Bright Minds Biosciences is not included in the Dow Jones index

When was Bright Minds Biosciences the previous earnings report?

No data

When does Bright Minds Biosciences earnings report?

Next earnings report date is not announced yet